

Department of Chemistry, Faculty of Food Technology
 J.J. Strossmayer University, Franje Kuhaca 18, 31 000 Osijek, Croatia
 PLIVA d.d.-Research Institute, Prilaz baruna Filipovica 25, 10 000 Zagreb, Croatia
 Faculty of Education, J.J. Strossmayer University, Lorentza Jagera 9, 31000 Osijek, Croatia
 Received August 30, 2002

3-Acyl-4-hydroxy-2-oxo-2*H*-chromen derivatives **1a-d** were condensed with (7-hydroxy-2-oxo-2*H*-chromen-4-yl)-acetic acid hydrazide **2**, (4-methyl-2-oxo-2*H*-chromen-7-yloxy)-acetic acid hydrazide **3**, and (7-hydrazinocarbonylmethoxy-2-oxo-2*H*-chromen-4-yl)-acetic acid hydrazide **4**, to give corresponding 3-alkyl-1-[2-(7-hydroxy-2-oxo-2*H*-chromeno-4-yl)-acetyl]-1*H*-chromeno[4,3-*c*]pyrazole-4-one **5a-d**, 3-alkyl-1-[2-(4-methyl-2-oxo-2*H*-chromeno-7-yloxy)-acetyl]-1*H*-chromeno[4,3-*c*]pyrazole-4-one **6a-d**, and 1-{4-[3-alkyl-1*H*-chromeno[4,3-*c*]pyrazole-4-one-1-yl]-carbonylmethyl}-2-oxo-2*H*-chromen-7-yloxy-acetyl}-3-alkyl-1*H*-chromeno[4,3-*c*]pyrazole-4-one **7a-d**.

J. Heterocyclic Chem., **40**, 833 (2002).

Since the coumarin ring forms a part of many heterocyclic compounds of pharmacological interest [1-4], these derivatives are being evaluated for potential biological activity. Different biological activity of the coumarins fused with other heterocycles in 3,4-positions [5-13] prompted the synthesis of coumarino[4,3-*c*]-N₁-substituted pyrazoles. Woulfson and Zhurin [14] reported the synthesis of coumarino[4,3-*c*]-N₁-phenyl-3-methylpyrazoles by cyclizing the phenylhydrazone of 3-acetyl-4-hydroxycoumarins using *p*-toluenesulphonic acid. Checchi and co-workers [15] condensed phenylhydrazine with 4-chloro-3-cyano-coumarins and obtained coumarino[4,3-*c*]-N₁-phenyl-3-aminopyrazoles. Moorty and co-workers [16] carried out the intramolecular cyclization of the phenylhydrazone of the respective 4-chloro-3-formylcoumarins using pyridine to which piperidine was added in traces. In this way the coumarino[4,3-*c*]-N₁-phenylpyrazoles were prepared. From 3-acetyl-4-hydroxy-2-oxo-2*H*-chromen, with hydrazine hydrate and phenylhydrazine in ethanol, were obtained 3-(1-hydrazonoethyl)-4-hydroxy-chromen-2-one and 3-methyl-1*H*-chromeno[4,3-*c*]pyrazole-4-one [17]. Klosa [18], under the same conditions, synthesised only 3-(1-hydrazono-ethyl)-4-hydroxy-chromen-2-one.

While in experiments performed so far, monopyrazole-coumarins were prepared [14-18], we succeeded in synthesis of a new pyrazole and dipyrazole, possesing two and even three coumarin nucleus.

Baker and co-workers [19] reported an unsuccessful attempt in (7-hydroxy-2-oxo-2*H*-chromen-4-yl)-acetic acid hydrazide **2** preparation from the corresponding methyl ester of the carboxylic acid. We succeeded in the preparation of the corresponding hydrazide [20] from (7-hydroxy-2-oxo-2*H*-chromen-4-yl)-acetic acid methyl ester, which was reacted with 100% hydrazine hydrate in methanol. (4-Methyl-2-oxo-2*H*-chromen-7-yloxy)-acetic acid ethyl ester was prepared by the reaction of 7-hydroxy-4-methyl-2-oxo-2*H*-chromen and ethylbromoacetate, which reacted with hydrazine hydrate in ethanol to give **3**. (7-Hydrazinocarbonylmethoxy-2-oxo-


2*H*-chromen-4-yl)-acetic acid hydrazide **4** was obtained from (7-hydroxy-2-oxo-2*H*-chromen-4-yl)-acetic acid. Compounds **1a-d** were synthesized from 4-hydroxy-2-oxo-2*H*-chromen [21-23]. Structures of compounds **1a-d** are as previously described [24-28]. Within these structures the α -pyrionic form is dominant, while the presence of the γ -pyrionic form is insignificant.

Refluxing an equimolar amounts of 3-acyl-4-hydroxy-2-oxo-2*H*-chromen **1** and **2** in ethanol led to a new series of compounds **5a-d**. (Scheme I). The same reaction when carried out by **3** and **4** leads to the fomation of **6a-d** and **7a-d** (Schemes II and III).

Screening Data.


Derivatives of coumarins **5a-d**, **6a-d** and **7a-d** described here were examined for their antimicrobial activity. The best results were obtained in the case of 1-[2-(7-hydroxy-2-oxo-2*H*-chromen-4-yl)-acetyl]-3-methyl-1*H*-chromeno[4,3-*c*]pyrazole-4-one **5a**, 3-ethyl-1-[2-(7-hydroxy-2-oxo-2*H*-chromen-4-yl)-acetyl]-1*H*-chromeno[4,3-*c*]pyrazole-4-one **5b**, 1-[2-(7-hydroxy-2-oxo-2*H*-chromen-4-yl)-acetyl]-3-propyl-1*H*-chromeno[4,3-*c*]pyrazole-4-one **5c** and 1-[2-(7-hydroxy-2-oxo-2*H*-chromen-4-yl)-acetyl]-3-isobutyl-1*H*-chromeno[4,3-*c*]pyrazole-4-one **5d**. These compounds were found to possess high antimicrobial activity against *Staphylococcus pneumoniae* and were slightly less active

Scheme I




against *Bacillus subtilis*, *Bacillus cereus* and *Salmonella panama*. In case of 3-alkyl-1-[2-(4-methyl-2-oxo-2*H*-chromeno[4,3-*c*]pyrazole-4-one **6a-d** and 1-{4-[3-alkyl-1*H*-chromeno[4,3-*c*]pyrazole-4-one-1-yl)-carbonylmethyl}-2-oxo-2*H*-chromen-7-yloxy-acetyl]-3-alkyl-1*H*-chromeno[4,3-*c*]pyrazole-4-one **7a-d**, we have found them to have very weak activity against all the tested microorganisms.

Scheme II



Scheme III



300 spectrometer (300 MHz) with tetramethylsilane as internal standard. The IR spectra (ν/cm^{-1}) were recorded as potassium bromide pellets on a Magna FT-IR 760 Nicolet spectrometer.

Starting from 4-hydroxy-2-oxo-2*H*-chromen using a known procedure, we have prepared 3-acyl-4-hydroxy-2-oxo-2*H*-chromen **1a-d** [21-23]. We have also used known procedures for the preparation of (7-hydroxy-2-oxo-2*H*-chromen-4-yl)-acetic acid hydrazide **2**.

Table I
Physical and Analytical Data for Compounds **5a-d**, **6a-d** and **7a-d**

Compound	R	Yield (%)	Mp (°C)	Formula (MW)	Analysis C	Calcd./H	Found (%) N
5a	-CH ₃	82	262 (402.6)	C ₂₂ H ₁₄ N ₂ O ₆ 65.43	65.67 3.80	3.51 6.80	6.96
5b	-CH ₂ CH ₃	76	265 (416.1)	C ₂₃ H ₁₆ N ₂ O ₆ 66.31	66.34 4.06	3.87 6.57	6.73
5c	-CH ₂ CH ₂ CH ₃	70	271 (430.4)	C ₂₄ H ₁₈ N ₂ O ₆ 66.94	66.97 4.36	4.22 6.24	6.51
5d	-CH ₂ CH(CH ₃) ₂	63	279 (444.4)	C ₂₅ H ₂₀ N ₂ O ₆ 67.47	67.54 4.48	4.54 6.41	6.30
6a	-CH ₃	78	249 (416.4)	C ₂₃ H ₁₆ N ₂ O ₆ 66.31	66.34 4.10	3.87 6.62	6.73
6b	-CH ₂ CH ₃	68	253 (430.4)	C ₂₄ H ₁₈ N ₂ O ₆ 66.73	66.97 4.48	4.22 6.44	6.51
6c	-CH ₂ CH ₂ CH ₃	72	259 (444.4)	C ₂₅ H ₂₀ N ₂ O ₆ 67.30	67.54 4.51	4.54 6.22	6.30
6d	-CH ₂ CH(CH ₃) ₂	58	265 (458.4)	C ₂₆ H ₂₂ N ₂ O ₆ 68.20	68.11 4.74	4.84 5.98	6.11
7a	-CH ₃	80	246 (642.57)	C ₃₅ H ₂₂ N ₄ O ₉ 65.57	65.42 3.40	3.45 8.92	8.72
7b	-CH ₂ CH ₃	82	248 (670.62)	C ₃₇ H ₂₆ N ₄ O ₉ 66.20	66.27 4.15	3.91 8.42	8.35
7c	-CH ₂ CH ₂ CH ₃	75	255 (698.68)	C ₃₉ H ₃₀ N ₄ O ₉ 67.06	67.04 4.23	4.33 8.04	8.02
7d	-CH ₂ CH(CH ₃) ₂	48	268 (726.73)	C ₄₁ H ₃₄ N ₄ O ₉ 67.87	67.76 4.84	4.72 7.80	7.71

EXPERIMENTAL

General Information.

Melting points were determined on a Fisher-Johns apparatus and are uncorrected. Microanalyses for C, H and N were performed on a Perkin-Elmer Analyzer 2400. The ¹H NMR spectra (δ values; DMSO-d₆ solutions) were recorded on a Varian Gemini

(4-Methyl-2-oxo-2*H*-chromen-7-yloxy)-acetic acid hydrazide (**3**).

A mixture of (4-methyl-2-oxo-2*H*-chromen-7-yloxy)-acetic acid ethyl ester (2.6 g, 0.01 mol) and 100% hydrazine hydrate (1 ml, 0.02 mol) in absolute ethanol (30 ml) was refluxed for 1.5 to 2.0 hours. The white precipitate which was formed during the reaction was collected by filtration, washed with water and crystallized

Table II
IR Data of Compounds **5a-d**, **6a-d** and **7a-d**

Compounds	v OH	v CH ₂	v CH ₃	IR (cm ⁻¹)	v C=O	v C=C	v C=N
5a	3422 w	3128 w	3008 s	1708 s	1651 s	1611 sh	
5b	3448 w	3175 w	3012 sh	1709 s	1692 s	1610 sh	
5c	3420 w	3181 w	3163 sh	1711 s	1641 s	1608 sh	
5d	3432 w	3160 w	3142 sh	1706 s	1654 s	1612 sh	
6a	-	3170 w	3120 sh	1712 s	1665 s	1605 sh	
6b	-	3165 w	3134 sh	1712 s	1690 s	1600 sh	
6c	-	3147 w	3020 sh	1705 s	1695 s	1610 sh	
6d	-	3160 w	3080 sh	1710 s	1694 s	1600 sh	
7a	-	3142 w	3004 sh	1718 s	1700 s	1612 sh	
7b	-	3120 w	2980 sh	1715 s	1695 s	1600 sh	
7c	-	3130 w	2995 sh	1712 s	1700 s	1600 sh	
7d	-	3140 w	3000 sh	1710 s	1705 s	1610 sh	

1617(C=C, arom.); ¹H NMR (DMSO-d₆): δ 9.34 (s, 1H, NH), 7.64 (d, 1H, H-5), 6.81(d, 1H, H-6), 6.78(s, 1H, H-8), 6.24 (s, 1H, H-3), 5.32 (s, 2H, CH₂), 3.24 (d, 2H, NH₂), 2.40 (s, 3H, CH₃).

Anal. Calcd. for C₁₂H₁₂N₂O₄: C, 58.06; H, 4.87; N, 11.29. Found: C, 58.12; H, 4.82; N, 10.98.

(7-Hydrazinocarbonylmethoxy-2-oxo-2*H*-chromen-4-yl)-acetic Acid Hydrazide (**4**).

In a solution containing methanol (120 ml) and 100% hydrazine hydrate (12 ml) was dissolved (7-ethoxycarbonylmethoxy-2-oxo-2*H*-chromen-4-yl)-acetic acid methyl ester (3.2 g, 0.01 mol) and the mixture was left to stand over night at 5 °C. The product was separated, was collected by suction filtration, washed with methanol, and recrystallized from dil. acetic acid.

M.p. >300°C, yield 2.14 g, (70%); IR (potassium bromide): v 3325; 3263 (NH), (NH₂), 1707; 1690 (C=O), 1623 (C=C, arom.). ¹H NMR (DMSO-d₆): δ 9.41 (s, 1H, NH), 9.34 (s, 1H, NH), 7.76 (d, 1H, H-5), 7.04 (d, 1H, H-6), 7.02 (s, 1H, H-8), 6.34 (s, 1H, H-3), 4.69 (s, 2H, CH₂), 4.34 (s, 2H, NH₂), 4.08 (s, 2H, CH₂), 3.38 (s, 2H, NH₂).

Anal. Calcd. For C₁₃H₁₄N₄O₅: C, 50.98; H, 4.61; N, 18.29. Found: C, 51.02; H, 4.38; N, 18.15.

General Procedure for Condensation and Cyclization of 3-Acyl-4-hydroxy-2-oxo-2*H*-chromen with Hydrazide **2,3** and Dihydrazide **4**.

A mixture of 3-acyl-4-hydroxy-2-oxo-2*H*-chromen **1a-d** (0.01 mole) and the corresponding hydrazide **2,3** (0.01 mole) in

Table III.
¹H NMR Data for Compounds **5a-d**, **6a-d** and **7a-d**

Compound	H-3 H-3'	H-5 H-5'	H-6 H-6'	H-7 H-7'	H-8 H-8'	R R'	-CH ₂ - -CH ₂ -	CH ₃
5a	- 6.74(s)	7.96(d) 7.32(d)	7.66(d) 6.82(d)	7.64(d) 10.62(s)	7.29(d) 6.75(d)	2.50(s) -	- 3.94(s)	-
5b	- 6.30(s)	7.95(d) 7.31(d)	7.67(q) 6.78(q)	7.63(d) 10.63(s)	7.29(d) 6.76(d)	3.15(q), 1.12(t) -	- 3.95(s)	-
5c	- 6.29(s)	7.96(d) 7.31(d)	7.65(d) 6.81(d)	7.64(d) 10.55(s)	7.26(d) 6.75(d)	3.07(t), 1.51(q), 0.94(t) -	- 3.94(s)	-
5d	- 6.26(s)	7.97(d) 7.34(d)	7.66(d) 6.80(d)	7.64(d) 10.58(s)	7.31(d) 6.72(d)	3.9(d); 0.89(d); 0.87(d) -	- 3.93(s)	-
6a	- 6.24(s)	7.98(d) 7.32(d)	7.72(d) 7.29(d)	- 7.63(d)	7.17(s) 7.05(d)	2.65(s) -	4.94(s) -	-
6b	- 6.24(s)	7.98(d) 7.32(d)	7.74(d) 7.28(d)	- 7.70(d)	7.30(s) 7.00(d)	3.11(q); 1.12(t) -	4.96(s) -	2.40(s)
6c	- 6.24(s)	7.96(d) 7.32(d)	7.72(d) 7.29(d)	- 7.66(d)	7.29(s) 7.06(d)	2.65(t); 2.50(q); 1.40(t) -	4.94(s) -	2.40(s)
6d	- 6.26(s)	7.94(d) 7.31(d)	7.74(d) 7.30(d)	- 7.78(d)	7.26(s) 7.00(d)	3.8(d), 0.92(d); 0.89(d) -	4.94(s) -	2.40(s)
7a	- 6.40(s)	8.25(d) 8.04(d)	7.84(d) 7.68-	- 7.40-	7.22(s) 7.09(d)	2.29(s) 2.50(s)	4.96(s) 4.02(s)	-
					7.17(d)			
7b	- 6.38(s)	8.02(d) 7.98(d)	7.84(d) 7.64-	- 7.38-	7.28(s) 7.08(d)	2.67(t); 1.16(t) -	4.97(s) 4.08(s)	-
					7.16(d)			
7c	- 6.37(s)	8.05(d) 7.98(d)	7.84(d) 7.64-	- 7.35-	7.28(s) 7.08(d)	2.60(t); 2.42(q); 1.40(t) -	4.97(s) 4.02(s)	-
					7.12(d)			
7d	- 6.39	7.99(d) 7.96(d)	7.87(d) 7.62-	- 7.32-	7.25(s) 7.00(d)	3.52(s); 1.15(d); 1.07(d) -	5.11(s) 4.00(s)	-
					7.14(d)			

from ethanol, m.p. 201-202 °C, yield 2.3 g (92.6%); IR (potassium bromide): v 3269; 3100 (NH), (NH₂), 1713; 1683 (C=O),

absolute ethanol (50 ml) was refluxed for 2 hours or at the end of the reaction (monitored by TLC). The reaction mixture was

cooled and solid was collected by filtration and recrystallized from ethanol.

In a similar manner to that described for the preparation of compounds **5a-d** and **6a-d**. By the action of 3-acyl-4-hydroxy-2-oxo-2H-chromen **1a-d** (0.02 mole) and dihydrazide **4** (0.01 mole) in absolute ethanol (75 ml), compounds **7a-d** were obtained. Data for yields, melting points, molecular formula and analyses are given in Table I. IR and ¹H NMR data are given in Table II and Table III.

REFERENCES AND NOTES

- [1] M. Lacova, J. Chovancova and V. Konecny, *Chem. Papers*, **40**, 121 (1986).
- [2] M. M. Badran, A.K. El Ansari and S. El Meligie, *Rev. Roum. Chim.*, **35**, 777 (1990).
- [3] S. S. El Morsy, A. A. Fadda, and M. S. El Hossini, *J. Indian Chem. Soc.*, **65**, 699 (1988).
- [4] M. Darbavar and V. Sundaramurthy, *Synthesis*, 337 (1982).
- [5a] D. Herber, *Arch. Pharm. (Weinheim)*, **320**, 577 (1987); [b] D. Herber, *Arch. Pharm. (Weinheim)*, **320**, 595 (1987).
- [6] R. Djudjic and M. Trkovnik, *Monatsh. Chem.*, **122**, 77 (1991).
- [7] T. Steinfuehrer, A. Hartschmann, M. Pietsch and M. Weissenfels, *Liebigs Ann. Chem.*, 23 (1992).
- [8] I. Ivanov, S. K. Karagiosov and M. F. Simeonov, *Liebigs Ann. Chem.*, 203 (1992).
- [9] M. A. Kirpichenok, V. M. Bakulev, L. A. Karandashova and I. I. Granberg, *Chem. Heterocycl. Compd. (Engl. Transl.)*, **27**, 1193 (1991).
- [10] E. Birckner, A. Hartschmann, T. Steinfuehrer and M. Weissenfels, German Patent (East) 2728853 (1989); *Chem. Abstr.*, **112**, 235283 (1990).
- [11] M. Weissenfels, A. Hantschmann, T. Steinfuehrer and E. Birkner, Z. *Chem.*, **29**, 166 (1989).
- [12] D. Herber, I. C. Ivanov and S. K. Karagiosov, *J. Heterocyclic Chem.*, **32**, 505 (1995).
- [13] Y. Kuroki, R. Akao, T. Inazumi and M. Noguchi, *Tetrahedron*, **50**, 1063 (1994).
- [14] S. Checchi and L. P. Vettori, *Gazz. Chim. Ital.*, **96**, 865 (1966); *Chem. Abstr.*, **65**, 16932 (1966).
- [15] N. S. Woulfson and R.B. Zhurin, *J. Gen. Chem. USSR*, **31**, 3381 (1961).
- [16] S. R. Moorty, V. Sundaramurthy and N. V. Suba Rao, *Indian J. Chem.*, **11**, 854 (1973).
- [17] A. Mustafa, O. H. Hishmat, A. A. Nawar and K. M. A. Khalil, *Liebigs Ann. Chem.*, **684**, 194 (1965).
- [18] J. Klosa, *Arch. Pharmaz. Ber. Dtsch. Pharmaz. Ges.*, **288**, 356 (1955).
- [19] W. Baker, C. N. Haksar and J. F. W. McOmie, *J. Chem. Soc.*, 170 (1950).
- [20] J. Krejcoves, J. Drobnik, J. Jokl, and J. Kalal, *Collect. Czech. Chem. Commun.*, **44**, 2211 (1979).
- [21] J. Klosa, *Arch. Pharm. Ber. Dtsch. Pharmaz. Ges.*, **288**, 356 (1955).
- [22] J. Klosa, *Arch. Pharm. Ber. Dtsch. Pharmaz. Ges.*, **289**, 104 (1956).
- [23] M. Dezelic and M. Trkovnik, *J. Med. Chem.*, **7**, 284 (1964).
- [24] T. Ukita, S. Nojima, M. Matsumoto, *J. Amer. Chem. Soc.*, **72**, 5143 (1950).
- [25] H. R. Eisenhauer, K. P. Link, *J. Amer. Chem. Soc.*, **75**, 2044 (1953).
- [26] N. Matzat, H. Wamhoff, F. Korte, *Chem. Ber.*, **102**, 3122 (1969).
- [27] M. Deželić, M. Trkovnik, M. Zovko, *Glas. Hem. Tehnol. BiH*, **9**, 5 (1969).
- [28] M. Deželić, M. Trkovnik, *Glas. Hem. Tehnol. BiH*, **12**, 17 (1973).